Pharmacodynamic activity of MEDI9197, a TLR7/8 agonist, administered intratumorally in subjects with solid subcutaneous or cutaneous tumors

被引：0

作者：

Cooper, Zachary A. ^{[1
]}

Morehouse, Christopher A. ^{[1
]}

Wu, Yuling ^{[1
]}

Steele, Keith ^{[1
]}

Brucker, David ^{[2
]}

Tseng, Leo ^{[1
]}

Jure-Kunkel, Maria ^{[1
]}

Mueller, Nancy ^{[1
]}

Ryan, Patricia ^{[1
]}

Grilley-Olson, Juneko ^{[3
]}

Hong, David ^{[4
]}

Marabelle, Aurelien ^{[5
]}

Munster, Pamela ^{[6
]}

Aggarwal, Rahul ^{[6
]}

Aspeslagh, Sandrine ^{[5
]}

Dixon, Robert G. ^{[3
]}

Patel, Manish ^{[7
]}

Subbiah, Vivek ^{[4
]}

Brody, Joshua ^{[8
]}

Gupta, Shilpa ^{[7
]}

机构：

[1] MedImmune, Gaithersburg, MD USA

[2] Definiens, Cambridge, MA USA

[3] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27515 USA

[4] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[5] Inst Gustave Roussy, F-94800 Villejuif, France

[6] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA

[7] Masonic Canc Ctr, Minneapolis, MN USA

[8] Mt Sinai Hess Ctr Sci & Med, New York, NY USA

来源：

JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2017年 / 5卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P457

引用

页数：2

共 39 条

[1] Safety and pharmacodynamic activity of MEDI9197, a TLR 7/8 agonist, administered intratumorally in subjects with solid tumors
Gupta, Shilpa
Grilley-Olson, Juneko
Hong, David
Marabelle, Aurelien
Munster, Pamela
Aggarwal, Rahul
Aspeslagh, Sandrine
Dixon, Robert G.
Patel, Manish
Subbiah, Vivek
Morehouse, Chris
Wu, Yuling
Zha, Jiping
Tseng, Leo
Cooper, Zachary A.
Morris, Shannon
Brody, Joshua
CANCER RESEARCH, 2017, 77
[2] A phase 1, first-time-in-human study of MEDI9197, a TLR7/8 agonist, administered intratumorally in subjects with a solid tumor cancer
Gupta, Shilpa
Tavakkoli, Fatemeh
Soukharev, Serguei
Gao, Guozhi
Morris, Shannon R.
Miller, Jeffrey S.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[3] Local immune activation resulting in tumor growth inhibition with MEDI9197-an intratumorally administered TLR7/8 agonist
Mullins, Stefanie
Grigsby, Iwen
Harrison, Lester I.
Ren, Song
Soukharev, Serguei
Young, Lesley
Elvecrog, James M.
Wilkinson, Robert W.
Tomai, Mark A.
Herbst, Ronald
Vasilakos, John P.
Leishman, Andrew J.
CANCER RESEARCH, 2016, 76
[4] Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies
Mullins, Stefanie R.
Vasilakos, John P.
Deschler, Katharina
Grigsby, Iwen
Gillis, Pete
John, Julius
Elder, Matthew J.
Swales, John
Timosenko, Elina
Cooper, Zachary
Dovedi, Simon J.
Leishman, Andrew J.
Luheshi, Nadia
Elvecrog, James
Tilahun, Ashenafi
Goodwin, Richard
Herbst, Ronald
Tomai, Mark A.
Wilkinson, Robert W.
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7 (01):
[5] Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies
Mullins, Stefanie R.
Vasilakos, John
Deschler, Katharina
Grigsby, Iwen
Ren, Song
Elder, Matthew J.
Dovedi, Simon J.
Leishman, Andrew J.
Ryan, Patricia
Cooper, Zachary
Elvecrog, James
Herbst, Ronald
Kumar, Rakesh
Tomai, Mark
Wilkinson, Robert W.
CANCER RESEARCH, 2018, 78 (13)
[6] Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment and holds potential for combination with immune checkpoint inhibitors
Mullins, Stefanie R.
Vogel, Katharina
Vasilakos, John
Grigsby, Iwen
Dovedi, Simon
Patricia, Ryan
Cooper, Zachary
Herbst, Ronald
Kumar, Rakesh
Tomai, Mark
Wilkinson, Robert W.
CANCER RESEARCH, 2017, 77
[7] Thermosensitive Gel-Based Formulation for Intratumoral Delivery of Toll-Like Receptor 7/8 Dual Agonist, MEDI9197
Fakhari, Amir
Nugent, Sean
Elvecrog, James
Vasilakos, John
Corcoran, Marta
Tilahun, Ashenafi
Siebenaler, Kristen
Sun, Jenny
Subramony, J. Anand
Schwarz, Alexander
JOURNAL OF PHARMACEUTICAL SCIENCES, 2017, 106 (08) : 2037 - 2045
[8] Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumors
Siu, Lillian
Brody, Joshua
Gupta, Shilpa
Marabelle, Aurelien
Jimeno, Antonio
Munster, Pamela
Grilley-Olson, Juneko
Rook, Alain H.
Hollebecque, Antoine
Wong, Rebecca K. S.
Welsh, James W.
Wu, Yuling
Morehouse, Christopher
Hamid, Oday
Walcott, Farzana
Cooper, Zachary A.
Kumar, Rakesh
Ferte, Charles
Hong, David S.
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)
[9] Systemically Administered TLR7/8 Agonist and Antigen-Conjugated Nanogels Govern Immune Responses against Tumors
Stickdorn, Judith
Stein, Lara
Arnold-Schild, Danielle
Hahlbrock, Jennifer
Medina-Montano, Carolina
Bartneck, Joschka
Ziss, Tanja
Montermann, Evelyn
Kappel, Cinja
Hobernik, Dominika
Haist, Maximilian
Yurugi, Hajime
Raabe, Marco
Best, Andreas
Rajalingam, Krishnaraj
Radsak, Markus P.
David, Sunil A.
Koynov, Kaloian
Bros, Matthias
Grabbe, Stephan
Schild, Hansjoerg
Nuhn, Lutz
ACS NANO, 2022, 16 (03) : 4426 - 4443
[10] BDB001, A TOLL-LIKE RECEPTOR 7 AND 8 (TLR7/8) AGONIST, CAN BE SAFELY ADMINISTERED INTRAVENOUSLY AND SHOWS CLINICAL RESPONSES IN ADVANCED SOLID TUMORS
Patel, Manish
Rasco, Drew
Johnson, Melissa
Tolcher, Anthony
Li, Lixin
Zong, Adam
Chung, Alexander
Andtbacka, Robert
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A199 - A199

← 1 2 3 4 →